Dalbavancin: A new lipoglycopeptide antibiotic

American Journal of Health-System Pharmacy

Volumn 65, Issue 7, 2008, Pages 599-610

  Bailey, Jennifer ^a   Summers, Kelly M ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Antibiotics; Bacterial infections; Dalbavancin; Dosage schedules; Drug interactions; Drugs, body distribution; Half life; Injections; Mechanism of action; Pharmacokinetics; Sustained action medications; Toxicity

Indexed keywords

CEFALEXIN; CEFAZOLIN; CEFTRIAXONE; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIMICROBIAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMISTRY; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; KIDNEY DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THRUSH;

EID: 41749091108     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070255     Document Type: Review

References (49)

1. Smith TL, Pearson ML, Wilox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999; 340:493-501.
2. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother. 2004; 38:2231-7.
3. Applebaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992; 15:77-83.
4. Morris JG, Shay DK, Hebden JN et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med. 1995; 123:250-9.
5. Panlilio AL, Culver DH, Gaynes RP et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals. Infect Control Hosp Epidemiol. 1992; 13:582-6.
6. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40:135-46.
7. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis. 2004; 17:549-55.
8. Potoski BA, Adams J, Clarke L et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis. 2006; 43:165-71.
9. Bonora MG, Solbiati M, Zorzi SE et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol. 2006; 44:1153-5.
10. Cuevas O, Cercenado E, Vindel A et al. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986-2002. Antimicrob Agents Chemother. 2004; 48:4240-5.
11. Anastasiou DM, Thorne GM, Luperchio SA et al. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents. 2006; 28:385-8.
12. Hayden MK, Rezai K, Hayes RA et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005; 43:5285-7.
13. Pfizer Inc. Pfizer receives approvable letter from FDA for dalbavancin. http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId= news_view&newsId=20071221005672&newsLang=en (accessed 2008 Jan 29).
14. Sosio M, Stinchi S, Beltrametti F et al. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by Nonomuraea species. Chem Biol. 2003; 10:541-9.
15. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005; 55(suppl S2):ii15-20.
16. Beauregard DA, Williams DH, Gwynn MN et al. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother. 1995; 39:781-5.
17. Nagarajan R. Minireview: antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother. 1991; 35: 605-9.
18. Allen NE, LeTourneau DL, Hobbs JN et al. Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies. Antimicrob Agents Chemother. 2002; 46:2344-8.
19. Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004; 48:137-43.
20. Goldstein EJ, Citron DM, Warren YA et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother. 2006; 50:2875-9.
21. Jones RN, Fritsche TR, Sader HS et al. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005; 17:593-600.
22. Streit JM, Sader HS, Fritsche TR et al. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn Microbiol Infect Dis. 2005; 53:307-10.
23. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol. 2006; 71:968-80.
24. Candiani G, Abbondi M, Borgonovi M et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semisynthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999; 44:179-92.
25. Lin G, Credito K, Ednie LM. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005; 49:770-2.
26. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against gram-positive clinical isolates from Latin America medical centres. Clin Microbiol Infect. 2005; 11:95-100.
27. Goosens H, Jabes D, Rossi R et al. European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates. J Antimicrob Chemother. 2003; 51(suppl S3):iii5-12.
28. Johnson DM, Fritsche TR, Sader HS et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006; 27:557-60.
29. Cavaleri M, Riva S, Valagussa A et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005; 55(suppl S2):ii31-5.
30. Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2003; 48:940-5.
31. Buckwalter M, Dowell AD. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005; 45:1279-87.
32. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003; 37:1298-303.
33. Micromedex Healthcare Series. DRUGDEX evaluations: Vancomycin. www.thomsonhc.com.proxy-hs.researchport.umd.edu/hcs/librarian (accessed 2007 Mar 3).
34. Micromedex Healthcare Series. DRUGDEX evaluations: Teicoplanin. www.thomsonhc.com.proxy-hs.researchport.umd.edu/hcs/librarian (accessed 2007 Mar 3).
35. Dowell J, Seltzer E, Stogniew M et al. Dalbavancin (DAL) pharmacokinetics (PK) in subjects with mild or moderate hepatic impairment (HI). In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004:4. Abstract.
36. Dowell JA, Seltzer E, Krause R et al. The safety and pharmacokinetics of dalbavancin in subjects with renal impairment or end-stage renal disease. Clin Microbiol Infect. 2005; 11(suppl 2):272. Abstract.
37. Dowell JA, Seltzer E, Stogniew M et al. Dalbavancin dosage adjustments not required for patients with mild renal impairment. Clin Microbiol Infect. 2003; 9(suppl 1):291. Abstract.
38. Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetics system. J Antimicrob Chemother. 2006; 58:802-5.
39. Jabes D, Candiani G, Romano G et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch model. Antimicrob Agents Chemother. 2004; 48:1118-23.
40. Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005; 40:374-80.
41. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005; 41:1407-15.
42. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin resistant Staphylococcus aureus infections. Clin Infect Dis. 2002; 34:1481-90.
43. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of 2 double-blind phase 3 comparisons with vancomycin-aztreonam. Clin Infect Dis. 2005; 41:S341-53.
44. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin-structure infections. Clin Infect Dis. 2004; 38:1673-81.
45. Nichols RL, Graham DR, Barrierre SL et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin. J Antimicrob Chemother. 1999; 44:263-73.
46. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006; 58:627-31.
47. Lexi-Comp Online. American Hospital Formulary Service drug information: vancomycin. http://online.lexi.com/crlsql/servlet/crlonline (accessed 2007 Mar 31).
48. Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005; 55(suppl S2):ii25-30.
49. McKesson Supply Management Online. https://supply.mckesson.com/portal/ site/smoportal/template.LOGIN/ (accessed 2007 Aug 29).